Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2004

View Archived Issues

Phase I data on the effects and safety of pemetrexed in breast cancer

New developments at Theratechnologies

BioMarin begins phase II trial of Phenoptin for PKU

U.S. phase IIb results for Technosphere Insulin, phase III begins in Europe

Cerus acquires mesothelin license from Chugai

Matritech refines NMP66 detection for breast cancer

Canadian approval for Cipralex

Centocor licenses rights to ImmunoGen's TAP technology

Vfend approved for candidemia in nonneutropenic patients

NDA submission for premature ejaculation treatment dapoxetine hydrochloride

Myriad Genetics files to begin phase I trial with MPC-2130

Treatment completed in phase III phenserine trial

Tipifarnib shows promise in the treatment of breast cancer

Phase II data on the effects of ZD-6474 in metastatic breast cancer

Ventavis approved for PAH

Update on the cognitive effects and safety profile of TC-1734

Contrast agents claimed by Fuji Photo Film

PTC develops compounds for diseases related to nonsense mutations of mRNA

Antitumor agents reported in patent literature

Yamanouchi team presents series of novel anticoagulants

IgG1 monoclonal antibodies for cancer therapy prepared and tested at Crucell

Finasteride tested to treat alcoholism

Clolar approved for pediatric ALL

Prialt receives FDA approval for severe chronic pain

Synthesis and preclinical efficacy of YM-75440, a novel, orally active squalene synthase inhibitor

Novel derivative of curcumin induces cell cycle arrest of HCT15 colon cancer cells

COX-2-derived prostacyclin is atheroprotective in female mice

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.